CELL ROBOTICS INTERNATIONAL, INC. has extended its intellectual property coverage of the Lasette product line by licensing a key patent from BD (formerly Becton, Dickinson and Company) of Franklin Lakes, NJ. Specific terms and conditions of the Agreement were not disclosed.
Dr. Ronald K. Lohrding, Cell Robotics’ President and CEO said, “We are delighted to have successfully completed this Agreement with BD. Combining Cell Robotics’ patents on various aspects of laser finger perforation with the license to BD’s intellectual property provides us with very strong patent protection for this revolutionary Lasette product line.”
The hand-held Lasette is the only FDA-cleared medical device that uses a special wavelength of laser light to obtain a capillary blood sample used for glucose readings and clinical blood screening tests.
Terry Hamilton, Lasette Marketing and Sales Manager of Cell Robotics, commented, “The pressure on health care institutions to comply with the ‘Needlestick Safety and Prevention Act’ requires them to move to safety-engineered devices. The Lasette is the only FDA- cleared needleless system available today. The Company sees a unique opportunity for the Lasette Plus’ Disposable Lens Covers to replace safety lancets at a comparable price at medical institutions. This also establishes a recurring revenue stream for the Company with its clinical customers. Medical facilities can benefit by completely eliminating needles from the ‘fingerstick’ procedure, thus eliminating one portion of their liability and the follow-up costs associated with accidental needlestick injuries.”
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.
BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products.
Cell Robotics International, Inc. is a medical products company striving to enhance patient quality-of-life through technology.